Once-Weekly Byetta LAR (exenatide long-acting release): So Far, It Works
It's a fact that Byetta reduces A1c's, post-meal and fasting glucose levels, and weight in people with type 2 diabetes. The drawback is that it's another injection twice a day. In response, Amylin, the maker of Byetta, has developed exenatide LAR, a form of Byetta that is injected only once a week.
A phase 2 clinical trial recently published in Diabetes Care has found that like Byetta, exenatide LAR improves blood glucose control and causes weight loss in people with type 2 diabetes. In the placebo-controlled study, exenatide LAR was given subcutaneously once weekly for 15 weeks to 45 patients with type 2 diabetes. At the outset, they were not well controlled on metformin or with diet and exercise, and their average A1c was 8.5 percent. Each patient on exenatide LAR received either 0.8 or 2.0 mg.
Both doses of the LAR formula reduced fasting plasma glucose and average daily blood glucose, both of which increased in the placebo group. A1c's increased slightly in the placebo group but decreased in the exenatide LAR patients, by 1.4 points in the 0.8 mg group and by 1.7 points in the 2.0 mg. group. The 2.0 mg LAR group lost an average of 8.4 pounds, but the 0.8 mg group and the placebo group lost no weight. No one had to discontinue the treatment due to adverse events.
Source: Diabetes Care 2007Click Here To View Or Post Comments